Hormone Treatment Side Effects for Transwomen May Increase Risk of Stroke, Blood Clots: Study

A new study warns that transgender persons taking hormones may face an increased risk of blood clots and strokes. 

Researchers from Kaiser Permanente indicate that cross-sex estrogen, used by transfeminine persons, appear to increase the risk of venous thromboembolism (VTE) and ischemic stroke. The findings were published July 10 in the Annals of Internal Medicine.

The research involves a cohort study looking at transgender members of integrated health care systems who declared transgender status from 2006 through 2014. Researchers then matched ten men and 10 female cisgender (born biologically female) subjects to the transgender patients using a number of factors, such as age and ethnicity.

Did You Know?

Ticketmaster Data Breach Impacts Millions of Customers

A massive Ticketmaster data breach exposed the names, addresses, phone numbers, credit card numbers and other personal information of more than 560 million customers, which have now been released on the dark web. Lawsuits are being pursued to obtain financial compensation.

Learn More

The study involved 2,842 transfeminine members (those transitioning to female), and 2,118 transmasculine members (those transitioning to male), as well as 48,686 cisgender men and 48,775 cisgender women, with a mean follow-up of up to four years. The researchers looked for incidence of venous thromboembolism, heart attack and stroke through 2016.

According to the findings, transfeminine subjects had a higher risk of venous thromboembolism, which can increase the risk of pulmonary embolism and deep vein thrombosis, than cisgender men and cisgender women. In addition, those transfeminine participants who began hormone therapy during the follow-up period showed more pronounced venous thromboembolism and ischemic stroke risks.

The researchers indicated that the data was insufficient to make conclusions regarding transmasculine subjects.

“The patterns of increases in VTE and ischemic stroke rates among transfeminine persons are not consistent with those observed in cisgender women,” the researchers determined. “These results may indicate the need for long-term vigilance in identifying vascular side effects of cross-sex estrogen.”

0 Comments

Share Your Comments

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

Zimmer Biomet CPT Hip System Linked to Increased Risk of Thigh Bone Fractures, FDA Warns
Zimmer Biomet CPT Hip System Linked to Increased Risk of Thigh Bone Fractures, FDA Warns (Posted today)

The FDA has issued a safety communication warning that Zimmer Biomet CPT hip system femoral stems may increase the risk of femur fractures, calling for doctors to avoid its use when possible.

Change Healthcare Data Breach Lawyers Meeting Today With MDL Judge For Initial Status Conference
Change Healthcare Data Breach Lawyers Meeting Today With MDL Judge For Initial Status Conference (Posted yesterday)

The judge presiding over all Change Healthcare lawsuits filed in federal court is holding the first status conference of the litigation, which is expected to grow significantly as Change Healthcare data breach letters continue to be sent to impacted customers.

Angiodynamics LifePort Lawsuit Filed Over Risk of the Port Catheters Failing, Causing Severe Injury
Angiodynamics LifePort Lawsuit Filed Over Risk of the Port Catheters Failing, Causing Severe Injury (Posted 2 days ago)

Complaint comes as a panel of federal judges are scheduled to hear oral arguments later this month, to determine whether all AngioDynamics port catheter lawsuits filed in U.S. District Courts nationwide should be centralized before one judge.